Edison Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
9
Active:2
Completed:3
Trial Phases
1 Phases
Phase 2:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
5 (100.0%)Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease
Phase 2
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: PTC-589
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Edison Pharmaceuticals Inc
- Target Recruit Count
- 44
- Registration Number
- NCT02462603
- Locations
- 🇺🇸
Cedar's Sinai, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Analysis of the Glutathione Cycle in Children With Rett Syndrome
Withdrawn
- Conditions
- Rett Syndrome
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Edison Pharmaceuticals Inc
- Registration Number
- NCT02360436
- Locations
- 🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]
- Conditions
- Leber's Hereditary Optic Neuropathy
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Edison Pharmaceuticals Inc
- Registration Number
- NCT02300753
- Locations
- 🇺🇸
Doheny Eye Institute / UCLA, Los Angeles, California, United States
Protective Effects of EPI-743 on Noise-Induced Hearing Loss
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Edison Pharmaceuticals Inc
- Target Recruit Count
- 77
- Registration Number
- NCT02257983
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Edison Pharmaceuticals Inc
- Registration Number
- NCT02226458
- Prev
- 1
- 2
- Next
News
No news found